Immune restoration with ibrutinib plus venetoclax in first-line chronic lymphocytic leukemia: the phase 2 CAPTIVATE study

We evaluated immune cell subsets in patients with chronic lymphocytic leukemia (CLL) who received first-line therapy with 3 cycles of ibrutinib then 13 cycles of ibrutinib plus venetoclax in the minimal residual disease (MRD) cohort of the CAPTIVATE study (NCT02910583). Patients with Confirmed undet...

Descripción completa

Detalles Bibliográficos
Autores principales: Moreno, Carol, Solman, Isabelle G., Tam, Constantine S., Grigg, Andrew, Scarfò, Lydia, Kipps, Thomas J., Srinivasan, Srimathi, Mali, Raghuveer Singh, Zhou, Cathy, Dean, James P., Szafer-Glusman, Edith, Choi, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2023
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10506056/
https://www.ncbi.nlm.nih.gov/pubmed/37315225
http://dx.doi.org/10.1182/bloodadvances.2023010236

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10506056/
https://www.ncbi.nlm.nih.gov/pubmed/37315225
http://dx.doi.org/10.1182/bloodadvances.2023010236

Ejemplares similares